# Case 011: The 10mg Catastrophe

> Standard CK monitoring at 6-12 weeks would have failed. Renal failure before first follow-up.

**Domain:** Statins/Pharma
**Signal:** Landmark
**Evidence type:** Case Report
**Patient:** 17M, Indian, Nephrotic Syndrome
**Source:** Pediatric Nephrology 2024 — Patel S, et al. (PMID: 38174231)
**Canonical URL:** https://zinda.health/cases/case-011-the-10mg-catastrophe-statin-rhabdomyolysis-indian-teen

## Summary

A 17-year-old Indian boy with nephrotic syndrome developed CK of 11,821 IU/L — 60x normal — within 4 days of starting atorvastatin 10mg. The case exposes a pharmacogenomic vulnerability specific to South Asian populations that standard monitoring protocols would have entirely missed.

## Presentation

The patient presented with nephrotic syndrome and began standard guideline-directed therapy, including atorvastatin 10mg daily for hypercholesterolemia. Baseline renal function was compromised but stable (CKD Stage 2). No genetic testing was performed prior to initiation.

## Key Finding

By day 4, the patient developed severe myalgias. Laboratory tests revealed a Creatine Kinase (CK) level of 11,821 IU/L — an extreme myotoxic response at the absolute minimum statin dose. South Asian populations frequently carry genetic variants in SLCO1B1 and CYP3A4 genes that dramatically reduce hepatic uptake and metabolism of statins.

## Intervention & Outcome

The statin was immediately discontinued. The patient required aggressive IV hydration to prevent progression to acute renal failure. Following statin cessation, CK levels normalized over two weeks. Pharmacogenomic testing was strongly recommended but was not yet standard protocol in this setting.

## Zinda Insight (Clinical Blindspot)

Standard guidelines call for CK monitoring at 6-12 weeks. This patient would have been in acute renal failure before his first scheduled follow-up. The SA pharmacogenomic difference here isn't marginal — it's the difference between a near-miss and a catastrophe. Rosuvastatin at 2.5-5mg or pitavastatin should be considered as first-line for SA patients requiring statin therapy.

## First Principles

Statins enter hepatocytes via the SLCO1B1 transporter. The SLCO1B1*5 variant (c.521T>C) is carried by ~15-20% of South Asians vs ~5-10% of Europeans. Each copy reduces transporter function ~50%. A homozygous carrier on 10mg has effective systemic exposure equivalent to 40mg in a wild-type European. Add CKD-impaired clearance and reduced muscle mass, and you have catastrophic myocyte exposure at 'minimum' doses.


## Framework Concepts

- The Fragile Engine
- The Missing Mechanics

## Conditions

- Nephrotic Syndrome
- Statin-Induced Rhabdomyolysis
- CKD


## Clinical Q&A

### Q: Why would a 10mg dose cause this?

South Asian populations frequently carry genetic variants in the SLCO1B1 and CYP3A4 genes that drastically reduce the hepatic uptake and metabolism of statins. A 10mg dose in a patient with these variants can result in systemic exposure equivalent to 40-80mg in a European patient.

### Q: Should South Asian patients avoid statins entirely?

No. Statins remain crucial for cardiovascular risk reduction. However, the choice of statin (hydrophilic vs lipophilic) and the starting dose must be tailored. Rosuvastatin and atorvastatin require much lower starting doses in this population.


## Patient-Facing Summary

### What Happened
A teenage boy from a South Asian family was started on a 'safe' minimum dose of a cholesterol-lowering pill. Within four days, his muscles began breaking down so severely that the muscle protein in his blood reached 60 times the normal level — enough to threaten his kidneys.

### Why It Matters
Cholesterol drugs (statins) are some of the most commonly prescribed medicines in the world. The standard doses were tested mostly on people of European ancestry. Many South Asians carry a small genetic variation that makes their body process these drugs very differently — a 'low' dose for a European can act like a 'high' dose for them.

### What You Can Do
If you or a family member is being started on a statin, ask whether the dose has been adjusted for South Asian metabolism, or if pharmacogenomic testing (a one-time saliva or blood test) is available. Watch for unexplained muscle pain, dark-colored urine, or weakness in the first few weeks and report it immediately.

### Questions to Ask Your Doctor
- Is there a lower starting dose appropriate for my background?
- Should I have an SLCO1B1 genetic test before starting?
- Could rosuvastatin or pitavastatin be safer for me than atorvastatin?
- When and how should we check my CK (muscle enzyme) level?


## Citation

When citing this case, attribute as: "Zinda Research Case 011: The 10mg Catastrophe, https://zinda.health/cases/case-011-the-10mg-catastrophe-statin-rhabdomyolysis-indian-teen, citing Pediatric Nephrology 2024 (PMID: 38174231)."